journal
MENU ▼
Read by QxMD icon Read
search

Journal of Parkinson's Disease

journal
https://www.readbyqxmd.com/read/27911344/patient-perspectives-on-deep-brain-stimulation-clinical-research-in-early-stage-parkinson-s-disease
#1
Lauren Heusinkveld, Mallory Hacker, Maxim Turchan, Madelyn Bollig, Christina Tamargo, William Fisher, Lauren McLaughlin, Adria Martig, David Charles
The FDA approved a multicenter, double-blind, Phase III, pivotal trial testing deep brain stimulation in 280 people with very early stage Parkinson's disease (PD; IDE#G050016). In partnership with The Michael J. Fox Foundation for Parkinson's Research, we conducted a survey to investigate motivating factors, barriers, and gender differences for participation in a trial testing DBS in early PD. The majority of survey respondents (72%) indicated they would consider learning more about participating. Men and women with early PD are likely to consider enrolling in trials of invasive therapies that may slow symptom progression and help future patients...
November 30, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27911343/pink1-parkin-and-mitochondrial-quality-control-what-can-we-learn-about-parkinson-s-disease-pathobiology
#2
Dominika Truban, Xu Hou, Thomas R Caulfield, Fabienne C Fiesel, Wolfdieter Springer
The first clinical description of Parkinson's disease (PD) will embrace its two century anniversary in 2017. For the past 30 years, mitochondrial dysfunction has been hypothesized to play a central role in the pathobiology of this devastating neurodegenerative disease. The identifications of mutations in genes encoding PINK1 (PTEN-induced kinase 1) and Parkin (E3 ubiquitin ligase) in familial PD and their functional association with mitochondrial quality control provided further support to this hypothesis. Recent research focused mainly on their key involvement in the clearance of damaged mitochondria, a process known as mitophagy...
November 30, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27911342/impulsive-and-compulsive-behaviors-in%C3%A2-parkinson-disease-the-norwegian-parkwest-study
#3
Aleksander H Erga, Guido Alves, Jan Petter Larsen, Ole Bj Rn Tysnes, Kenn Freddy Pedersen
BACKGROUND: Impulsive and compulsive behaviors (ICBs) are frequent in Parkinson's disease (PD), but data from population-based cohorts is lacking. OBJECTIVES: To determine the frequency and associated demographic, clinical, neuropsychiatric and cognitive features of ICBs in a population-based PD cohort. METHODS: This cross-sectional study included 125 patients with PD and 159 age- and gender-matched normal controls recruited from the Norwegian ParkWest study...
November 30, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27911341/longer-duration-of-mao-b-inhibitor-exposure-is-associated-with-less-clinical-decline-in-parkinson-s-disease-an%C3%A2-analysis%C3%A2-of%C3%A2-net-pd-ls1
#4
Robert A Hauser, Ruosha Li, Adriana Pérez, Xuehan Ren, Dan Weintraub, Jordan Elm, John L Goudreau, John C Morgan, John Y Fang, Michael J Aminoff, Chadwick W Christine, Rohit Dhall, Chizoba C Umeh, James T Boyd, Natividad Stover, Maureen Leehey, Richard M Zweig, Anthony P Nicholas, Ivan Bodis-Wollner, Allison Willis, Karl Kieburtz, Barbara C Tilley
BACKGROUND: Monoamine oxidase type B (MAO-B) inhibitors exhibit neuroprotective effects in preclinical models of PD but clinical trials have failed to convincingly demonstrate disease modifying benefits in PD patients. OBJECTIVE: To perform a secondary analysis of NET-PD LS1 to determine if longer duration of MAO-B inhibitor exposure was associated with less clinical decline. METHODS: The primary outcome measure was the Global Outcome (GO), comprised of 5 measures: change from baseline in the Schwab and England (ADL) scale, the 39-item Parkinson's Disease Questionnaire (PDQ-39), the UPDRS Ambulatory Capacity Scale, the Symbol Digit Modalities Test, and the most recent Modified Rankin Scale...
November 30, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27911340/dementia-predictors-in-parkinson-disease-a-validation-study
#5
Julius Bm Anang, Takashi Nomura, Silvia Rios Romenets, Kenji Nakashima, Jean-Francois Gagnon, Ronald B Postuma
In a prospective study, we recently discovered 8 clinical predictors of dementia in Parkinson's disease. Here, we validate these dementia predictors using two additional prospective cohorts (n = 134). After a 3.6-year follow-up, 35/134 developed dementia (7.2% per year). When confirming individual variables, 5/8 were significantly associated with dementia in the validation cohort. These included age, male sex, baseline RBD, orthostatic hypotension, and MCI. Bilateral onset, hallucinations and falls/freezing did not significantly predict dementia; however, point estimates of OR were all >1...
November 30, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27911321/the-effects-of-meditation-on-grey-matter-atrophy-and-neurodegeneration-a%C3%A2-systematic-review
#6
Nicole Last, Emily Tufts, Leslie E Auger
The present systematic review is based on the premise that a variety of neurodegenerative diseases are accompanied by grey matter atrophy in the brain and meditation may impact this. Given that age is a major risk factor for many of these progressive and neurodegenerative diseases and that the percentage of the population over the age of 65 is quickly increasing, there is an obvious need for prompt treatment and prevention advances in research. As there is currently no cure for Alzheimer's disease and other neurodegenerative diseases, many are seeking non-pharmacological treatment options in attempts to offset the disease-related cognitive and functional declines...
November 26, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27858720/challenges-of-improving-patient-centred-care-in-parkinson-s-disease
#7
Soania Mathur, Leah Mursaleen, Jon Stamford, Steve DeWitte, Israel Robledo, Tom Isaacs
BACKGROUND: Parkinson's disease is a neurodegenerative condition with a complex pattern of motor and non-motor symptoms. Of several clinical scales used to measure patient experience few are delivered by patients themselves. OBJECTIVE: The present study reports the results of an online survey to establish (a) factors that most influence QoL (quality of life) for people with Parkinson's and (b) areas where self-monitoring may help. METHODS: A 27 question online survey (using Survey Monkey) was developed by The Cure Parkinson's Trust, comprising four main sections (demographics, monitoring, symptoms and communication)...
November 14, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27858719/regular-exercise-quality-of-life-and-mobility-in-parkinson-s-disease-a%C3%A2-longitudinal-analysis-of-national-parkinson-foundation-quality-improvement-initiative-data
#8
Miriam R Rafferty, Peter N Schmidt, Sheng T Luo, Kan Li, Connie Marras, Thomas L Davis, Mark Guttman, Fernando Cubillos, Tanya Simuni
BACKGROUND: Research-based exercise interventions improve health-related quality of life (HRQL) and mobility in people with Parkinson's disease (PD). OBJECTIVE: To examine whether exercise habits were associated with changes in HRQL and mobility over two years. METHODS: We identified a cohort of National Parkinson Foundation Quality Improvement Initiative (NPF-QII) participants with three visits. HRQL and mobility were measured with the Parkinson's Disease Questionnaire (PDQ-39) and Timed Up and Go (TUG)...
November 14, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27792016/epigenetic-biomarkers-for-parkinson-s-disease-from-diagnostics-to-therapeutics
#9
Jennifer L Jakubowski, Viviane Labrie
Parkinson's disease (PD) is a prevalent neurodegenerative illness that is often diagnosed after significant pathology and neuronal cell loss has occurred. Biomarkers of PD are greatly needed for early diagnosis, as well as for the prediction of disease progression and treatment outcome. In this regard, the epigenome, which is partially dynamic, holds considerable promise for the development of molecular biomarkers for PD. Epigenetic marks are modified by both DNA sequence and environmental factors associated with PD, and such marks could serve as a unifying predictor of at-risk individuals...
October 25, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27802244/sexual-preoccupation-behavior-in%C3%A2-parkinson-s-disease
#10
Gila Bronner, Sharon Hassin-Baer, Tanya Gurevich
People with Parkinson's disease (PD) present with problematic sexual behaviors that are often misunderstood or ignored. Sexual problems in PD are part of a non-motor syndrome, and they play a  prominent role in the life of affected individuals and their partners. Based on our considerable clinical experience, we describe four common types of sexual preoccupation behaviors in people with PD: (1) sexual behavior with underlying sexual dysfunction, (2) sexual desire discrepancy with partner after restored desire, (3) hypersexuality and compulsive sexual behavior, and (4) sexual behavior with underlying restless genital syndrome...
October 12, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27802243/the-proteasome-inhibition-model-of%C3%A2-parkinson-s-disease
#11
Eduard Bentea, Lise Verbruggen, Ann Massie
The pathological hallmarks of Parkinson's disease are the progressive loss of nigral dopaminergic neurons and the formation of intracellular inclusion bodies, termed Lewy bodies, in surviving neurons. Accumulation of proteins in large insoluble cytoplasmic aggregates has been proposed to result, partly, from a failure in the function of intracellular protein degradation pathways. Evidence in support for such a hypothesis emerged in the beginning of the years 2000 with studies demonstrating structural and functional deficits in the ubiquitin-proteasome pathway in post-mortem nigral tissue of patients with Parkinson's disease...
October 11, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27802242/effects-of-safinamide-on-pain-in-fluctuating-parkinson-s-disease-patients-a-post-hoc-analysis
#12
Carlo Cattaneo, Paolo Barone, Erminio Bonizzoni, Marco Sardina
BACKGROUND: Pain, a frequent non-motor symptom in Parkinson's Disease (PD), significantly impacts on quality of life. Safinamide is a new drug with dopaminergic and non-dopaminergic properties, approved in Europe as adjunct therapy to levodopa for the treatment of fluctuating PD patients. Results from two 24-month, double-blind, placebo-controlled studies demonstrated that safinamide has positive effects on both motor functions and quality of life in PD patients. OBJECTIVE: To investigate the effects of safinamide on pain management in PD patients with motor fluctuations using pooled data from studies 016 and SETTLE...
October 11, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27689617/clinical-complexity-and-use-of%C3%A2-antipsychotics-and-restraints-in%C3%A2-long-term-care-residents-with%C3%A2-parkinson-s-disease
#13
George A Heckman, Alexander M Crizzle, Jonathen Chen, Tamara Pringsheim, Nathalie Jette, Marie-Jeanne Kergoat, Leslie Eckel, John P Hirdes
BACKGROUND: Patients with Parkinson's disease (PD) and/or Parkinsonism are affected by a complex burden of comorbidity. Many ultimately require institutional care, where they may be subject to the application of physical restraints or the prescription of antipsychotic medications, making them more vulnerable to adverse outcomes. OBJECTIVES: The objectives of this paper are to: 1) describe the clinical complexity of older institutionalized persons with PD; and 2) examine patterns and predictors of restraint use and prescription of antipsychotics in this population...
September 29, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27768000/author-index-volume-6-2016
#14
(no author information available yet)
No abstract text is available yet for this article.
October 19, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27662333/tremor-frequency-assessment-by-iphone%C3%A2-applications-correlation-with-emg-analysis
#15
Rui Araújo, Miguel Tábuas-Pereira, Luciano Almendra, Joana Ribeiro, Marta Arenga, Luis Negrão, Anabela Matos, Ana Morgadinho, Cristina Januário
Tremor frequency analysis is usually performed by EMG studies but accelerometers are progressively being more used. The iPhone® contains an accelerometer and many applications claim to be capable of measuring tremor frequency. We tested three applications in twenty-two patients with a diagnosis of PD, ET and Holmes' tremor. EMG needle assessment as well as accelerometry was performed at the same time. There was very strong correlation (Pearson >0.8, p < 0.001) between the three applications, the EMG needle and the accelerometry...
October 19, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27662332/muscarinic-m1-receptor-coupling-to-g-protein-is-intact-in-parkinson-s-disease-dementia
#16
Jasinda H Lee, Paul T Francis, Clive G Ballard, Dag Aarsland, Raj N Kalaria, Peter T-H Wong, Christopher P Chen, Mitchell K P Lai
BACKGROUND: Postsynaptic cholinergic deficits, including reduced cortical muscarinic M1 receptor coupling to G-proteins, are neurochemical findings postulated to underlie the limited efficacy of presynaptically-targeted cholinergic replacement therapies in Alzheimer's disease (AD). While the loss of M1-G-protein coupling has been associated with β-amyloid (Aβ) burden in AD, the status of M1 coupling to G-proteins in Parkinson's disease-related or mixed dementias is unclear. OBJECTIVE: To test the hypothesis that M1 receptor uncoupling is correlated with Aβ burden, we aimed to study muscarinic M1 neurochemical parameters in neurodegenerative dementias characterized by low and high Aβ loads...
October 19, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27662331/the-practicalities-of-assessing-freezing-of%C3%A2-gait
#17
Claudia Barthel, Elizabeth Mallia, Bettina Debû, Bastiaan R Bloem, Murielle Ursulla Ferraye
BACKGROUND: Freezing of gait (FOG) is a mysterious, complex and debilitating phenomenon in Parkinson's disease. Adequate assessment is a pre-requisite for managing FOG, as well as for assigning participants in FOG research. The episodic nature of FOG, as well as its multiple clinical expressions make its assessment challenging. OBJECTIVE: To highlight the available assessment tools and to provide practical, experience-based recommendations for reliable assessment of FOG...
October 19, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27662330/subjective-perceived-motor-improvement-after-acute-levodopa-challenge-in-parkinson-s-disease
#18
Constance Rabel, Floriane Le Goff, Romain Lefaucheur, Gulden Ozel, Damien Fetter, Audrey Rouillé, David Maltête
BACKGROUND: Previous studies found a poor association between parkinsonian patient's reported subjective improvement after commencing dopaminergic treatment and improvements in objective measures of motor impairment by clinician. OBJECTIVE: To compare PD patient's subjective perceived motor improvement after acute levodopa challenge test with objective motor improvement assessed by the clinician using the UPDRS part III. To analyze clinical characteristics, i.e...
October 19, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27662329/evaluating-the-efficacy-of-nocturnal-continuous-subcutaneous-apomorphine-infusion-in-sleep-disorders-in-advanced-parkinson-s-disease-the-apo-night-study
#19
Gustavo Fernández-Pajarín, Ángel Sesar, Begoña Ares, Alfonso Castro
BACKGROUND: There are not many data about the beneficial effect of nocturnal continuous subcutaneous apomorphine infusion (NCSAI) over sleep disturbances in advanced Parkinson's disease (PD). OBJECTIVE: Evaluate the effect of the NCSAI in sleeping problems and insomnia due to nocturnal hypokinesia inadvanced PD. METHODS: We assessed 17 advanced PD patients with several sleep disturbances measured by SCOPA-SLEEP and PDSS scales. All the patients were on apomorphine infusion during daytime...
October 19, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27662328/personalized-medicine-approaches-in-parkinson-s-disease-the-genetic-perspective
#20
Thomas Gasser
Recent discoveries with respect to the genetic and molecular basis of Parkinson's disease have led to an increasing recognition of the etiologic heterogeneity of the disorder. As in other complex diseases, it is hoped that this knowledge will allow the identification of novel therapeutic targets that will eventually lead to a more efficient treatment, based on the patient's individual genetic predispositions.
October 19, 2016: Journal of Parkinson's Disease
journal
journal
43718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"